Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: influenza DNA vaccines - Inovio

Drug Profile

Research programme: influenza DNA vaccines - Inovio

Alternative Names: GLS-3700; H3HA DNA vaccine - Inovio; H3N2 influenza DNA vaccine - Inovio; H7N9 influenza DNA vaccine - Inovio; Influenza A virus H7N9 DNA vaccine - Inovio; Pandemic influenza DNA vaccine - Inovio; Prophylactic pre-pandemic influenza DNA vaccine cocktail (VGX-3500) - Inovio; Seasonal influenza DNA vaccine - Inovio; SynCon™ universal flu vaccine - Inovio; Universal Flu DNA Vaccine - Inovio; Universal Influenza DNA Vaccine - Inovio; VGX 3500; VGX-3500 (H5 + H1) DNA vaccine; VGX-3500X

Latest Information Update: 21 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inovio Biomedical Corporation; VGX International
  • Developer Inovio Pharmaceuticals
  • Class Influenza A virus H1N1 vaccines; Influenza A virus H5N1 vaccines; Influenza A virus H7N9 vaccines; Influenza virus DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype
  • No development reported Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype; Influenza virus infections

Most Recent Events

  • 17 Sep 2018 Preclinical development is ongoing in Influenza-A-virus-H1N1-subtype (Prevention) in USA (Parenteral, Injection)
  • 17 Sep 2018 Preclinical trials in Influenza-A virus H3N2 subtype (Prevention) in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A virus H7N9 subtype(Prevention) in Canada (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top